These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25575975)

  • 1. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.
    Burgess SV; Mabasa VH; Chow I; Ensom MH
    Ann Pharmacother; 2015 Mar; 49(3):311-22. PubMed ID: 25575975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
    Mah GT; Mabasa VH; Chow I; Ensom MH
    Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
    Perrott J; Mabasa VH; Ensom MH
    Ann Pharmacother; 2010 Mar; 44(3):557-64. PubMed ID: 20124468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
    Burgess DS; Hastings RW; Hardin TC
    Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous and extended infusions of β-lactam antibiotics in the pediatric population.
    Walker MC; Lam WM; Manasco KB
    Ann Pharmacother; 2012 Nov; 46(11):1537-46. PubMed ID: 23115223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of i.v. push administration on β-lactam pharmacodynamics.
    Butterfield-Cowper JM; Burgner K
    Am J Health Syst Pharm; 2017 May; 74(9):e170-e175. PubMed ID: 28438821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
    Tam VH; Louie A; Lomaestro BM; Drusano GL
    Pharmacotherapy; 2003 Mar; 23(3):291-5. PubMed ID: 12627925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
    Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
    Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged versus Intermittent Infusion of Antibiotics in Acute and Severe Infections: A Meta-analysis.
    Luo J; Liao J; Cai R; Liu J; Huang Z; Cheng Y; Yang Z; Liu Z
    Arch Iran Med; 2019 Oct; 22(10):612-626. PubMed ID: 31679364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
    Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
    J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.